NCT07107932

A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

A Large-Sample Real-World Dynamic Cohort Registry: Observing the Clinical Outcomes of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 10,000 (estimated)
• Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Conditions

• Tetanus

Interventions

Type	Name	Description
DRUG	Siltartoxatug Injection (Brand name: Sintetol®)	The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Timeline

• Start date: 2025-07-31
• Primary completion: 2029-03-30
• Completion: 2029-03-30
• First posted: 2025-08-06
• Last updated: 2026-01-06

Locations

4 sites across 1 country: China

Regulatory

• FDA-regulated drug study